美多芭联合盐酸普拉克索治疗帕金森病非运动症状的临床效果

Clinical effect of madopar combined pramipexole hydrochloride on non-motor symptoms in Parkinson’s disease

目的探讨美多芭联合盐酸普拉克索治疗帕金森病非运动症状的临床效果。方法将110例帕金森患者随机分为对照组和观察组,每组55例。对照组采用美多芭治疗,观察组给予美多芭联合盐酸普拉克索治疗,疗程均为3个月。治疗前后采用简易智能精神状态检查量表(MMSE)和蒙特利尔认知量表(MoCA)分别评估患者的精神状态和认知能力,采用抑郁自评量表(SDS)和焦虑自评量表(SAS)分别评估患者抑郁和焦虑情况。比较两组患者不良反应发生情况。结果治疗后,观察组患者MMSE和MoCA得分均高于对照组,SDS、SAS评分和不良反应总发生率均低于对照组(均P<0.05)。结论美多芭联合盐酸普拉克索治疗帕金森病能有效改善患者的非运动症状,不良反应少。

Objective To explore the clinical effect of madopar combined pramipexole hydrochloride on non-motor symptoms in Parkinson′s disease. Methods A total of 110 patients with Parkinson′s disease were randomly divided into control group and observation group,with 55 cases in each group.The control group was given madopar,while the observation group was treated with madopar and pramipexole hydrochloride,both groups were treated for 3 months .Before and after treatment,patients′ mental state and cognitive function were evaluated by the Mini-Mental Status Examination(MMSE) scale and the Montreal Cognitive Assessment(MoCA) scale,and their conditions of depression and anxiety were evaluated by the Self-Rating Depression Scale(SDS) and the Self-Rating Anxiety Scale(SAS).The incidence of adverse reactions was compared between the two groups. Results After treatment,the observation group obtained higher MMSE and MoCA scores,lower SDS and SAS scores and total incidence rate of adverse reactions compared with the control group(all P <0.05). Conclusion The combination of madopar and pramipexole hydrochloride can effectively improve non-motor symptoms,with fewer adverse reactions,in the treatment of Parkinson′s disease.